Do Statins Increase the Risk of Idiopathic Polyneuropathy?

Anderson, Jeffrey L.; Muhlestein, Joseph B; Bair, Tami L; Morris, Steven; Weaver, Aaron N.; Lappé, Donald; Renlund, Dale G.; Pearson, Robert R.; Jensen, Kurt; Horne, Benjamin D.

doi:10.1016/j.amjcard.2004.12.068

Cited by 22 publications

(25 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If it occurs at all, it would be extremely uncommon, causing 1 case for every 2200 person-years of statin use. 62,63 Neoplasm Although several animal studies have suggested that statin therapy is associated with an increased risk of cancer, 64 meta-analyses of 5 randomized clinical trials involving 30 817 patients found no association between statin use over a 4-to 6-year period and the risk of fatal or nonfatal cancer. 65 To the contrary, there are now numerous reports suggesting that statins may actually be beneficial in reducing the risk of certain neoplasms.…”

Section: Neuropathymentioning

confidence: 97%

The Role of Statin Drugs in the Management of the Peripheral Vascular Patient

Samson

2008

Vasc Endovascular Surg

View full text Add to dashboard Cite

The impact of statin therapy on established vascular conditions and recurrent disease is most relevant for long-term care. Patients receiving statin therapy have been shown to experience less recurrent stenosis following carotid endarterectomy and stent angioplasty, reduced cardiac events following cardiac and noncardiac vascular surgery, and reduction in aneurysm development. In patients with peripheral arterial disease, claudication distance is increased, as well as patency rates following infrainguinal arterial bypass grafting. Of note, statins drugs may also prove beneficial in the prevention of certain cancers, Alzheimer's disease, and osteoporosis (all diseases frequently seen concurrently in the patient with peripheral arterial disease). As such, it is becoming all the more necessary that vascular surgeons remain informed about clinical research initiatives related to statin use and lipid management in general. The following is a review of lipid metabolism as it applies to statins as well as a review of the beneficial effects of statins.

show abstract

Section: Neuropathymentioning

confidence: 97%

The Role of Statin Drugs in the Management of the Peripheral Vascular Patient

Samson

2008

Vasc Endovascular Surg

View full text Add to dashboard Cite

show abstract

“…Odds ratios were calculated as 4.6% overall with current users of statins compared with controls and 16.1% with defi nite neuropathy compared with controls. However, potential pitfalls complicate the study, especially whether all symptomatic neuropathy causes were in fact excluded, including associated conditions requiring statin treatment (eg, occult diabetes, glucose intolerance, metabolic syndrome, simple hyperlipidemia) [48,49]. Despite the rarity of the association, the large number of patients who take these medications makes the association potentially clinically relevant, a common patient concern, and a source of considerable litigation.…”

Section: Lipid-lowering Agentsmentioning

confidence: 98%

Update on medication-induced peripheral neuropathy

Weimer

Sachdev²

2008

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Despite improvements in the identification of causes of peripheral neuropathy, idiopathic polyneuropathy remains common. Medication and toxic neuropathy account for a small but important percentage of potentially preventable or reversible causes of neuropathy. New drugs that can induce neuropathy have been approved over the past several years, including the anticancer agents bortezomib, ixabepilone, and oxaliplatin. We review the neurotoxic effects of tumor necrosis factor-alpha blockers infliximab and etanercept, the inflammatory arthritis agent leflunomide, and the antibiotic linezolid. The controversy of statin-induced neuropathy continues to unfold; the large Fremantle Diabetes Study has suggested that statins may have neuroprotective effects. Dichloroacetate is a promising agent for lactic acidosis-associated disorders, but toxic neuropathy is a treatment-limiting factor. We also describe a progressive inflammatory neuropathy in swine slaughterhouse workers that appears to be a toxin-induced immune response.

show abstract

“…15 The risk is increased by longer duration of statin use and the cumulative dose. 4,7,9 Partial or complete recovery after statin cessation has been described. 12,14,15 A case of mononeuropathy multiplex and a case of a disorder resembling GuillainBarré also have been described both after simvastatin use.…”

Section: Discussionmentioning

confidence: 99%

“…3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have become a dominant lipid-lowering pharmacotherapy 4 and are widely used. 5 The best recognized and most commonly reported adverse effects are muscular.…”

mentioning

confidence: 99%